^
    27d
    TQB2223-AK105-Ib-01: Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma. (clinicaltrials.gov)
    P1, N=34, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Anniko (penpulimab) • TQB2223
    9ms
    Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma. (clinicaltrials.gov)
    P1, N=34, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P1 trial • Metastases
    |
    Anniko (penpulimab) • TQB2223
    over1year
    TQB2223 Injection in Combination With Penpulimab in Patients With Advanced Cancers (clinicaltrials.gov)
    P1, N=92, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P1 trial • Combination therapy • Metastases
    |
    LAG3 (Lymphocyte Activating 3)
    |
    Anniko (penpulimab) • TQB2223